Zydus Lifesciences: Company Gets US FDA Priority Review For Saroglitazar NDA To Treat PBC.

 27 May 2026 05:33 PM

Zydus Lifesciences: Company Gets US FDA Priority Review For Saroglitazar NDA To Treat PBC.

Zydus Life: Co To Join Bank Of America India Conference In Mumbai On June 2, 2026.

 23 May 2026 03:37 PM

Zydus Life: Co To Join Bank Of America India Conference In Mumbai On June 2, 2026.

Zydus Life: Expects Consolidated Revenue To Grow In The High Teens For FY27. North American Business Anticipated To Grow In The Single Digits, While India's Branded Formulations Projected To Exceed Market Growth By 200 To 400 Basis Points.

 20 May 2026 09:03 AM

Zydus Life: Expects Consolidated Revenue To Grow In The High Teens For FY27. North American Business Anticipated To Grow In The Single Digits, While India's Branded Formulations Projected To Exceed Market Growth By 200 To 400 Basis Points.

Zydus Life: Expects Strong Growth In International Markets And Consumer Wellness, With EBITDA Margin Projected Over 24% For FY27 Despite Competition And Saro Launch Costs.

 20 May 2026 09:03 AM

Zydus Life: Expects Strong Growth In International Markets And Consumer Wellness, With EBITDA Margin Projected Over 24% For FY27 Despite Competition And Saro Launch Costs.

Zydus Life: Plans To Invest INR 70 Million For Saro Commercialization And A Total Capex Of About INR 1,500 Crore For FY27, With Quarterly Depreciation Estimated At INR 550 Crore. Management Anticipates India's Business Will Surpass Market Growth By 200 To 400 Basis Points In FY27.

 20 May 2026 09:04 AM

Zydus Life: Plans To Invest INR 70 Million For Saro Commercialization And A Total Capex Of About INR 1,500 Crore For FY27, With Quarterly Depreciation Estimated At INR 550 Crore. Management Anticipates India's Business Will Surpass Market Growth By 200 To 400 Basis Points In FY27.

Zydus Life: Expects FY27 EBITDA Margins To Go Beyond 24%, Considering Competition From Mirabegron And Launch Expenses For Saro, With R&D Costs Estimated Over 8%. The Biosimilars Business In India Is A Significant Contributor, Surpassing INR 800 Crores, And Global Expansion Is Anticipated By FY29-30.

 20 May 2026 09:04 AM

Zydus Life: Expects FY27 EBITDA Margins To Go Beyond 24%, Considering Competition From Mirabegron And Launch Expenses For Saro, With R&D Costs Estimated Over 8%. The Biosimilars Business In India Is A Significant Contributor, Surpassing INR 800 Crores, And Global Expansion Is Anticipated By FY29-30.

Zydus Life: Jefferies maintains a Buy on Zydus Life with a Target Price of ₹1200, citing a strong Q4 beat driven by US specialty traction, sustainable US base business, steady India performance, robust international growth, strong FTF and innovative product pipeline, and a 14% FY28 EPS upgrade from new launches.

 20 May 2026 08:55 AM

Zydus Life: Jefferies maintains a Buy on Zydus Life with a Target Price of ₹1200, citing a strong Q4 beat driven by US specialty traction, sustainable US base business, steady India performance, robust international growth, strong FTF and innovative product pipeline, and a 14% FY28 EPS upgrade from new launches.

Zydus Life: JPMorgan maintains a Neutral on Zydus Life with a Target Price of ₹1050, citing a strong Q4 beat with broad-based growth and margin expansion, FY27 guidance for high-teens revenue growth and 24%+ EBITDA margins, strong US pipeline visibility despite expected Mirabegron erosion from Sept 2027, and a 10% FY27 earnings upgrade.

 20 May 2026 08:55 AM

Zydus Life: JPMorgan maintains a Neutral on Zydus Life with a Target Price of ₹1050, citing a strong Q4 beat with broad-based growth and margin expansion, FY27 guidance for high-teens revenue growth and 24%+ EBITDA margins, strong US pipeline visibility despite expected Mirabegron erosion from Sept 2027, and a 10% FY27 earnings upgrade.

Zydus Lifesciences: Company's Board Gives Green Light for Buyback of 95.65 Lakh Shares at ₹1,150 Each, Totaling ₹1,100 Crore.

 19 May 2026 08:03 PM

Zydus Lifesciences: Company's Board Gives Green Light for Buyback of 95.65 Lakh Shares at ₹1,150 Each, Totaling ₹1,100 Crore.

Zydus Life: Expects Revenue Growth In The High Teens For FY27, With Single Digit Sales Growth In North America, And An Anticipated EBITDA Margin Of 24% For FY27.

 19 May 2026 04:43 PM

Zydus Life: Expects Revenue Growth In The High Teens For FY27, With Single Digit Sales Growth In North America, And An Anticipated EBITDA Margin Of 24% For FY27.

Zydus Life: Co. Board Sets May 29, 2026, As Record Date For Share Buyback.

 19 May 2026 02:17 PM

Zydus Life: Co. Board Sets May 29, 2026, As Record Date For Share Buyback.

Zydus Lifesciences: India's Formulations Business Sees 14% Increase to ₹1753 Crore Year-Over-Year.

 19 May 2026 02:26 PM

Zydus Lifesciences: India's Formulations Business Sees 14% Increase to ₹1753 Crore Year-Over-Year.

Zydus Life: Co Reports 18% Revenue Growth for FY26 Vs Guidance for Double Digit Growth.

 19 May 2026 02:27 PM

Zydus Life: Co Reports 18% Revenue Growth for FY26 Vs Guidance for Double Digit Growth.

ZYDUS LIFESCIENCES: CO APPROVED BUYBACK SHARES AT PRICE OF RS 1150 PER SHARE VIA TENDER OFFER

 19 May 2026 02:15 PM

ZYDUS LIFESCIENCES: CO APPROVED BUYBACK SHARES AT PRICE OF RS 1150 PER SHARE VIA TENDER OFFER

ZYDUS LIFESCIENCES: Q4 CONS NET PROFIT 13B RUPEES VS 11.7B (YOY)

 19 May 2026 02:08 PM

ZYDUS LIFESCIENCES: Q4 CONS NET PROFIT 13B RUPEES VS 11.7B (YOY)

ZYDUS LIFESCIENCES: Q4 REVENUE 76B RUPEES VS 65.3B (YOY)

 19 May 2026 02:09 PM

ZYDUS LIFESCIENCES: Q4 REVENUE 76B RUPEES VS 65.3B (YOY)

ZYDUS LIFESCIENCES: Q4 EBITDA 25.5B RUPEES VS 21.26B (YOY) || Q4 EBITDA MARGIN 33.7% VS 32.56% (YOY)

 19 May 2026 02:09 PM

ZYDUS LIFESCIENCES: Q4 EBITDA 25.5B RUPEES VS 21.26B (YOY) || Q4 EBITDA MARGIN 33.7% VS 32.56% (YOY)

Zydus Lifesciences: Co. To Buy Assertio Holdings Listed On NASDAQ For ₹1,592 Cr ($193 Million) In Cash At $23.50 Per Share, Enhancing Its Position In The U.S. Specialty And Pain Management Pharmaceuticals Market. - BL

 14 May 2026 09:04 AM

Zydus Lifesciences: Co. To Buy Assertio Holdings Listed On NASDAQ For ₹1,592 Cr ($193 Million) In Cash At $23.50 Per Share, Enhancing Its Position In The U.S. Specialty And Pain Management Pharmaceuticals Market. - BL

Zydus Lifesciences: Subsidiary Zydus Worldwide DMCC Set to Buy Entire Stake in Nasdaq-Listed Assertio Holdings for $23.50 Per Share, Amounting to $166.4 Million

 13 May 2026 08:41 PM

Zydus Lifesciences: Subsidiary Zydus Worldwide DMCC Set to Buy Entire Stake in Nasdaq-Listed Assertio Holdings for $23.50 Per Share, Amounting to $166.4 Million

Zydus Lifesciences: Board Meeting Planned To Discuss Share Buyback Proposal On May 19, 2026.

 13 May 2026 04:00 PM

Zydus Lifesciences: Board Meeting Planned To Discuss Share Buyback Proposal On May 19, 2026.